Stem cell treatment for acute myocardial infarction

Fisher, Sheila; Zhang, Huajun; Dorée, Carolyn; Mathur, Anthony; Martin‐Rendon, Enca

doi:10.1002/14651858.cd006536.pub4

Cited by 237 publications

(114 citation statements)

References 188 publications

Supporting

Mentioning

107

Contrasting

Order By: Relevance

“…108,109 Thus, considering the low regeneration potential of the endogenous mechanisms attempts to stimulate regeneration by using exogenous stem cells seem plausible. 110,111 Stem cell therapy has been reported to have beneficial effects in patients who had previously suffered a myocardial infarction. This issue, although controversial and not the focus of the present review, has been recently reviewed by Fisher et al 111 and Wang et al 112 …”

Section: Myocardial Infarctionmentioning

confidence: 99%

See 1 more Smart Citation

Tracking stem cells with superparamagnetic iron oxide nanoparticles: perspectives and considerations

Jasmin¹,

Souza²,

Louzada³

et al. 2017

IJN

View full text Add to dashboard Cite

Superparamagnetic iron oxide nanoparticles (SPIONs) have been used for diagnoses in biomedical applications, due to their unique properties and their apparent safety for humans. In general, SPIONs do not seem to produce cell damage, although their long-term in vivo effects continue to be investigated. The possibility of efficiently labeling cells with these magnetic nanoparticles has stimulated their use to noninvasively track cells by magnetic resonance imaging after transplantation. SPIONs are attracting increasing attention and are one of the preferred methods for cell labeling and tracking in preclinical and clinical studies. For clinical protocol approval of magnetic-labeled cell tracking, it is essential to expand our knowledge of the time course of SPIONs after cell incorporation and transplantation. This review focuses on the recent advances in tracking SPION-labeled stem cells, analyzing the possibilities and limitations of their use, not only focusing on myocardial infarction but also discussing other models.

show abstract

Section: Myocardial Infarctionmentioning

confidence: 99%

“…110,111 Stem cell therapy has been reported to have beneficial effects in patients who had previously suffered a myocardial infarction. This issue, although controversial and not the focus of the present review, has been recently reviewed by Fisher et al 111 and Wang et al 112 …”

Section: Myocardial Infarctionmentioning

confidence: 99%

Tracking stem cells with superparamagnetic iron oxide nanoparticles: perspectives and considerations

Jasmin¹,

Souza²,

Louzada³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…[22][23][24] By contrast, other trials failed to show LV function improvement, although they demonstrated reduction in infarct size, [25][26][27][28] whereas others failed to report any benefit. [29][30][31][32] Two recently published meta-analyses 33,34 showed similar results: cell treatment led to significant improvement in LVEF (by 2%-5%) when measured by echocardiography, single-photon emission computed tomography, and left ventriculography, but not with magnetic resonance imaging (MRI).…”

Section: Introductionmentioning

confidence: 92%

Stem‐cell therapy in ST‐segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double‐blind randomized trial

Nicolau

Furtado

Silva

et al. 2018

Clinical Cardiology

View full text Add to dashboard Cite

BackgroundLeft ventricular ejection fraction (LVEF) is a major determinant of long‐term prognosis after ST‐segment elevation myocardial infarction (STEMI). STEMI patients with reduced LVEF have a poor prognosis, despite successful reperfusion and the use of renin‐angiotensin‐aldosterone inhibitors.HypothesisIntracoronary infusion of bone marrow–derived mononuclear cells (BMMC) may improve LVEF in STEMI patients successfully reperfused.MethodsThe main inclusion criteria for this double‐blind, randomized, multicenter study were patient age 30 to 80 years, LVEF ≤50%, successful angioplasty of infarct‐related artery, and regional dysfunction in the infarct‐related area analyzed before cell injection. Cardiac magnetic resonance imaging was used to assess LVEF, left ventricular volumes, and infarct size at 7 to 9 days and 6 months post–myocardial infarction.ResultsOne hundred and twenty‐one patients were included (66 patients in the BMMC group and 55 patients in the placebo group). The primary endpoint, mean LVEF, was similar between both groups at baseline (44.63% ± 10.74% vs 42.23% ± 10.33%; P = 0.21) and at 6 months (44.74% ± 12.95 % vs 43.50 ± 12.43%; P = 0.59). The groups were also similar regarding the difference between baseline and 6 months (0.11% ± 8.5% vs 1.27% ± 8.93%; P = 0.46). Other parameters of left ventricular remodeling, such as systolic and diastolic volumes, as well as infarct size, were also similar between groups.ConclusionsIn this randomized, multicenter, double‐blind trial, BMMC intracoronary infusion did not improve left ventricular remodeling or decrease infarct size.

show abstract

“…[1][2][3][4][5][6] In 2014, the DAMASCENE group has revealed several discrepancies in published clinical trials with regenerative medicine. 7 In 2017, it is likely that Crosstalk between transcription factors involved in the formation of the first and second heart field (light grey box).…”

mentioning

confidence: 99%

Cardiac Stem Cell-based Regenerative Therapy for the Ischemic Injured Heart — a Short Update 2017

Gyöngyösi

Lukovic

Zlabinger

et al. 2017

Journal of Cardiovascular Emergencies

View full text Add to dashboard Cite

Cell therapy for the ischemic injured heart has been largely investigated in the last two decades, and most of the small cohort and randomized clinical studies, as well as meta-analyses led to the conclusion that cell-based human regenerative therapy is safe and effective in term of reducing adverse clinical outcomes and increasing left ventricular performance. Both the in vitro and in vivo rodent animal models of ischemic heart failure using bone marrow-derived mononuclear cells promised marvelous success in regeneration of the heart suffering from ischemic burden. However, in certain patient groups, stem cell studies failed to reach the pri- for patients with ischemic heart disease with the hope of clinically relevant regeneration of the human ischemic injured myocardium by using bone marrow cells, but also peripheral progenitors, cardiospheres, or mesenchymal

show abstract

Stem cell treatment for acute myocardial infarction

Cited by 237 publications

References 188 publications

Tracking stem cells with superparamagnetic iron oxide nanoparticles: perspectives and considerations

Tracking stem cells with superparamagnetic iron oxide nanoparticles: perspectives and considerations

Stem‐cell therapy in ST‐segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double‐blind randomized trial

Cardiac Stem Cell-based Regenerative Therapy for the Ischemic Injured Heart — a Short Update 2017

Contact Info

Product

Resources

About